Effect of Rifaximin on Gut Bacterial Flora Post Stem Cell Transplant in Patients With Acute Leukemia

Randomized Trial to Study the Effect of Rifaximin on Gut Microbiome Diversity Post Allogeneic Stem Cell Transplant in Acute Leukemia.

• Goal: This study is a randomized phase II interventional study. The purpose of this study is to see if addition of oral rifaximin tablets during allogeneic stem cell transplant can improve the quality of gut microbiome and reduce chances of death, infections and graft versus host disease (GVHD) post-transplant.
• The study objectives are as follows:
• Primary Objective: To determine the impact of rifaximin on gut microbial diversity and compare it with controls.
• Secondary Objectives: a. To determine non-relapse mortality at 1-year post transplant in patients who receive peri-transplant transplant rifaximin and compare it with controls.
• b. To compare the incidence of severe GVHD in patients who receive peri-transplant rifaximin with the controls.
• c. To determine impact of gut decontamination with rifaximin on incidence of MDR sepsis and usage of higher antibiotics (e.g. Carbapenems, colistin, tigecycline, ceftazidime avibactum and ceftriaxone-sulbactam EDTA) in first 6 months post BMT.
• d. To determine the impact of rifaximin induced gut manipulation on immune reconstitution, T cell repertoire post-transplant and cytokine profile.
• Exploratory objective: To use single cell transcriptomics (SCT) to identify immune cell profile in gut biopsies post allogeneic stem cell transplant whenever biopsy is done, to correlate the impact of microbiome on gut immunity.
• Intervention: Tab Rifaximin 200 mg will be given orally twice daily from day -8 to day +60 of allogeneic stem cell transplant in acute leukemia patients. This will be in addition to standard of care post-transplant treatment.
• Comparator Agent: Standard of care treatment including standard anti GVHD measures, antibiotic support and transfusions as needed.

Study Overview

• Status: Not yet recruiting
• Conditions: Acute Leukemia
• Intervention / Treatment: Drug: Rifaximin with allogeneic stem cell transplant; Procedure: Allogeneic stem cell transplant

Detailed Description

The gut microbiome plays a significant role in modulating the immune re-constitution post allogeneic stem cell transplant (ASCT). Low gut microbial diversity has been consistently associated with poor outcomes of transplant including increased incidence of acute graft versus host disease (aGVHD), post-transplant bacterial sepsis and non-relapse mortality (NRM). However, the exact mechanism by which gut microbiome influences local as well as systemic immunity is not completely known, and is thought to be due to the impact of microbial metabolites on intestinal epithelial cells and host antigen-presenting cells. Understanding these mechanisms and modulating the microbiome may be crucial to improving transplant outcomes. Rifaximin is a locally acting antibiotic that has been approved for manipulating the gut microbiome in hepatic failure. It is unique because of its ability to clear pathogenic bacteria, while preserving the anaerobic commensals. It can potentially modify the gut microbiome to increase the alpha diversity and this may help reduce aGVHD, infectious complications, and mortality post-transplant. High incidence of multidrug resistant sepsis and frequent use of broad spectrum antibiotics in India, would result in higher rates of dysbiotic gut- making microbiome manipulation to improve transplant outcomes more relevant in our country. We are proposing a randomized controlled trial to understand the benefits of modulating the gut microbiome in patients of ASCT while investigating the local and global immune repertoire using single cell sequencing and multicolour flow cytometry.

Study design: Single center, open-labeled, phase II study, randomized controlled trial.

Primary Objective: To determine the impact of rifaximin on gut microbial alpha diversity and compare it with controls.

Secondary Objectives:

To determine impact of rifaximin on 1 year non relapse mortality post-transplant, incidence of grade III/IV aGVHD, incidence of MDR sepsis, patterns of immune cell reconstitution, and cytokine profile post-transplant.

Exploratory objective: To use single-cell transcriptomics (SCT) to identify immune cell profiles in gut biopsies post ASCT in order to get insights into the impact of the microbiome on local gut immunity.

Study population: Adult patients who undergo ASCT at the Tata Memorial Centre.

Study Methodology in brief: Patients would be randomized to receive either oral tablet rifaximin 200 mg twice daily along with standard posttransplant treatment or to receive standard of care treatment alone. Stool samples and blood samples will be collected at different time points for microbiome analysis and immune cell profiling respectively. We plan to perform 16s rRNA-based next-generation sequencing of all variable regions using a phased primer approach using stool DNA as a template. Gut microbiome diversity will be calculated using the inverse Simpson index. Immune cell profile would be analyzed using 16 color flow cytometry. In selected cases where patients undergo colonoscopic gut biopsy for aGVHD, we will also obtain samples for transcriptome sequencing. This will help us understand how immune cells interact with gut mucosa and microbiome in patients of aGVHD

• Study Type: Interventional
• Enrollment (Estimated): 166
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Dr. Anant Gokarn, DM; Phone Number: 8685 +91-02268735000; Email: anantgokarn@gmail.com
• Study Contact Backup: Name: Dr.Sumeet Mirgh, DM; Phone Number: 8685 +91-02268735000; Email: drsumeetmirgh@gmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Adults with acute leukemia undergoing allogeneic stem cell transplant.
• ECOG performance status 0, 1 or 2.
• Adequate Liver function

Exclusion Criteria:

• Known hypersensitivity to rifaximin or other rifampicin antimicrobial agents
• Current or past history of inflammatory bowel disease
• History of major bowel resection or presence of colostomy.
• Ongoing Verapamil, ketoconazole or itraconazole.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Tab Rifaximin with Allogeneic stem cell transplant; Tab Rifaximin 200 mg will be given orally twice daily from day -8 to day +60 of allogeneic stem cell transplant in acute leukemia patients. This will be in addition to standard of care post transplant treatment	Drug: Rifaximin with allogeneic stem cell transplant; Tab Rifaximin 200 mg will begiven orally twice daily from day -8 to day +60 of allogeneic stem cell transplant in acute leukemia patients. This will be in addition to standard of care posttransplant treatment
Active Comparator: Allogeneic stem cell transplant; Allogeneic stem cell transplant: Standard of care treatment including standard anti GVHD measures, antibiotic support and transfusions as needed.	Procedure: Allogeneic stem cell transplant; Standard of care treatment including standard anti GVHD measures, antibiotic support and transfusions as needed.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Impact of rifaximin on gut microbial diversity.	Gut microbial diversity as measured by inverse Simpson index (ISI) on stool samples on day 14 post transplant in Rifaximin arm and in controls.	14 days post transplant

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Non relapse mortality	Non relapse mortality (NRM) at 1 year post transplant in patients who receive peri-transplant transplant rifaximin and in controls	1 year post transplant
Incidence of severe (grade III/IV) acute graft versus host disease	Incidence of severe (grade III/IV) acute graft versus host disease (aGVHD) in patients who receive peri-transplant rifaximin and in control arm.	1 year post transplant
Impact of gut decontamination with rifaximin on incidence of multidrug resistant sepsis post transplant.	Incidence of multidrug resistant (MDR) sepsis and usage of higher antibiotics (e.g. Carbapenems, colistin, tigecycline, ceftazidime avibactam and ceftriaxone-sulbactam EDTA) in first 6 months post BMT in both rifaximin arm and in controls.	6 months post transplant
Impact of rifaximin induced gut manipulation on immune reconstitution	Immune-reconstitution, T cell repertoire post transplant as measured by multicolor flow-cytometry in patients who receive rifaximin and in controls.	1 year post transplant

Collaborators and Investigators

• Sponsor: Tata Memorial Centre
• Investigators: Principal Investigator: Dr. Anant Gokarn, Gokarn, Advanced Centre for Treatment, Research and Education in Cancer

Study record dates

Study Major Dates

• Study Start (Estimated): October 15, 2023
• Primary Completion (Estimated): October 15, 2026
• Study Completion (Estimated): October 15, 2026

Study Registration Dates

• First Submitted: September 21, 2023
• First Submitted That Met QC Criteria: September 21, 2023
• First Posted (Actual): September 28, 2023

Study Record Updates

• Last Update Posted (Actual): October 16, 2023
• Last Update Submitted That Met QC Criteria: October 12, 2023
• Last Verified: September 1, 2023

More Information

Terms related to this study

• Keywords: Rifaximin; Gut Microbiome
• Additional Relevant MeSH Terms: Pathologic Processes; Neoplasms by Histologic Type; Neoplasms; Disease Attributes; Leukemia; Acute Disease; Anti-Infective Agents; Gastrointestinal Agents; Anti-Bacterial Agents; Rifaximin
• Other Study ID Numbers: 900872

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: No not shared

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No